Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2012
Date:11/6/2012

CARLSBAD, Calif., Nov. 6, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $26.0 million and $36.0 million for the three and nine months ended September 30, 2012, respectively, compared to a pro forma NOL of $20.0 million and $44.9 million for the same periods in 2011. The Company ended the third quarter of 2012 with $343.6 million in cash. 

"We have had a very successful year. With a number of exciting events on the horizon, the remainder of 2012 promises to be equally eventful. Of course, the most notable events this year are associated with KYNAMRO™. We are pleased with the positive recommendation from the FDA's advisory committee for KYNAMRO and look forward to the FDA's decision early next year. We believe KYNAMRO could have a profound impact on the lives of patients with homozygous FH, who are at extreme cardiovascular risk and are in need of new therapeutic options. We look forward to bringing this important new medicine to these patients," said B. Lynne Parshall, Chief Operating Officer and Chief Financial Officer at Isis. 

"While KYNAMRO is the most notable of our successes, we have had many achievements across our pipeline. Most recently, we have completed key steps to move two of our severe and rare disease drugs toward commercial markets. We initiated the next clinical study in patients with spinal muscular atrophy for our drug, ISIS-SMNRx, which we partnered with Biogen Idec earlier this year. This study will be a relatively short study and will position us to initiate a registration-directed Phase 2/3 study next year. In addition, we and GSK amended the development plan for ISIS-TTRRx to employ a more efficient route to the market. We plan to initiate the Phase 2/3 study evaluating ISIS-TTRRx'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. MEI Pharma Reports New Data Showing High Response Rates in Clinical Trial of Pracinostat and Azacitidine in Myelodysplastic Syndrome
2. CVS Caremark Reports Third Quarter Results
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
4. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
5. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
6. Depomed Reports Third Quarter Financial Results
7. Cambrex Reports Third Quarter 2012 Financial Results
8. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. Express Scripts Reports Third Quarter Results
10. ADVENTRX Reports Third Quarter 2012 Financial Results
11. Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 ... the addition of the  "Global Operating Room ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An ... sterile environment in a healthcare facility used ... with technically advanced equipment, which ensures patient ...
(Date:8/22/2014)...  As the Medical Affairs, role has become more ... area are exploring methods to develop strong capabilities to ... at Best Practices, LLC is designed to give Medical ... key challenges they face. The consortium will provide a ... roundtable discussions where leaders discuss key findings from the ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... conference call and a live Internet webcast along with a ... ET (7:00 a.m. PT) to discuss results for the 2010 ... to participate on this call is (877) 295-5743, confirmation code ...
... MYL ) today announced that its subsidiary ... and 200 mg, under a previously announced settlement and ... company to have filed a substantially complete ANDA containing ... awarded 180 days of marketing exclusivity.   ...
Cached Medicine Technology:Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:8/22/2014)... 2014 Recently, iFitDress.com, a well-known wedding ... of discounted wedding gowns . In addition to ... these new products are provided with low shipping fees. ... to unveil the new wedding gowns. In our online ... for ladies to choose from. What’s more, all of ...
(Date:8/22/2014)... New Orleans, LA The LSU Health New ... Advanced Education Nursing Traineeship grant to increase access ... disadvantaged, underserved and under-represented groups, as well as ... the US Department of Health and Human Services ... will serve as the grant,s project director., The ...
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Restore My Vision Today , ... Pearson to help people discover how they can get ... by instead improving their eyesight naturally has caught the ... , “There’s a reason why the glasses and contacts ... because people just assume that it’s their only option ...
Breaking Medicine News(10 mins):Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2
... disease could be more common than thought, experts say, , ... from rabies of a 17-year-old Texas girl -- diagnosed months ... their heads and wondering if such cases might be less ... possibility that abortive rabies can occur in humans and might ...
... ... enterprise platform for its revolutionary Evercore® – Enterprise Clinical Suite software system, now available ... ... Healthcare Technology , a leading medical informatics company, has launched a new enterprise platform ...
... ... ... ... ...
... , ... ... ... ...
... screening tool for early detection of prostate cancer (PCa) in ... PCa. The risk of suicide is increased among cancer patients ... among men diagnosed with PCa subsequent to PSA testing, a ... published in the March issue of European Urology , ...
... Two Spanish psychologists and a German neurologist have recently shown ... new noun is different from the part used when a ... taken using functional magnetic resonance, according to an article they ... "Learning nouns activates the left fusiform gyrus, while learning ...
Cached Medicine News:Health News:Texas Girl Recovers From Rabies Without Intensive Care 2Health News:TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 3Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 4Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 5Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 6Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 7Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 8Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 9Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 10Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 11Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 12Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 13Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 14Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 15Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 16Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 17Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 18Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 19Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 20Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 21Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 22Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 23Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 24Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 25Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 26Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 27Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 28Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 29Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 30Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 31Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 32Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 33Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: